Literature DB >> 27965308

Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma.

Naoshad Muhammad1, Sourav Bhattacharya1, Robert Steele1, Nancy Phillips1, Ratna B Ray2,3.   

Abstract

Purpose: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Although improvements in surgical techniques, chemotherapy and radiation delivery, and supportive care have improved quality of life for patients with HNSCC, regional and distant recurrence remain common. Recent evidence suggests that cancer stem-like cells (CSC) play a significant role in recurrence and chemoresistance. We previously observed that c-Fos was highly upregulated in the HNSCC sphere-forming cells. Consequences of c-Fos upregulation for the biology of HNSCC-CSCs are poorly understood. In this study, we investigated the role of c-Fos in renewal of stemness of HNSCC and tumor growth.Experimental Design and
Results: We generated stable HNSCC cell lines ectopically expressing the c-Fos gene. Exogenous expression of c-Fos in nontumorigenic MDA1386Tu cells makes these cells tumorigenic in nude mice. Furthermore, subcutaneous transplantation of c-Fos-overexpressing Cal27 cells (tumorigenic) into immunocompromised mice enhanced tumor growth as compared with parental cells. Mechanistic investigations demonstrated that c-Fos overexpression enhanced the epithelial-mesenchymal transition (EMT) state and expression of CSC markers (Nanog, c-Myc, Sox2, and Notch1). Ectopic expression of c-Fos in HNSCC cells also displays increased sphere formation. We further observed that overexpression of c-Fos increased the expression of pERK and cyclin D1 in HNSCC cells.Conclusions: Together, our results strongly suggest a novel role of c-Fos as a regulator of EMT and cancer stem cell reprogramming in HNSCC cells, which may hold potential as a CSC-directed therapeutic approach to improve HNSCC treatment. Clin Cancer Res; 23(12); 3120-8. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27965308      PMCID: PMC5468504          DOI: 10.1158/1078-0432.CCR-16-2811

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  36 in total

1.  Activation of the NOTCH pathway in head and neck cancer.

Authors:  Wenyue Sun; Daria A Gaykalova; Michael F Ochs; Elizabeth Mambo; Demetri Arnaoutakis; Yan Liu; Myriam Loyo; Nishant Agrawal; Jason Howard; Ryan Li; Sun Ahn; Elana Fertig; David Sidransky; Jeffery Houghton; Kalyan Buddavarapu; Tiffany Sanford; Ashish Choudhary; Will Darden; Alex Adai; Gary Latham; Justin Bishop; Rajni Sharma; William H Westra; Patrick Hennessey; Christine H Chung; Joseph A Califano
Journal:  Cancer Res       Date:  2013-12-18       Impact factor: 12.701

Review 2.  AP-1 as a regulator of cell life and death.

Authors:  Eitan Shaulian; Michael Karin
Journal:  Nat Cell Biol       Date:  2002-05       Impact factor: 28.824

Review 3.  New advances in molecular approaches to head and neck squamous cell carcinoma.

Authors:  Nivedita Sahu; Jennifer Rubin Grandis
Journal:  Anticancer Drugs       Date:  2011-08       Impact factor: 2.248

4.  CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer.

Authors:  T J Liu; B C Sun; X L Zhao; X M Zhao; T Sun; Q Gu; Z Yao; X Y Dong; N Zhao; N Liu
Journal:  Oncogene       Date:  2012-04-02       Impact factor: 9.867

5.  Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1.

Authors:  Paula Monje; Javier Hernández-Losa; Ruth J Lyons; Maria D Castellone; J Silvio Gutkind
Journal:  J Biol Chem       Date:  2005-08-25       Impact factor: 5.157

6.  Role of DNA 5-methylcytosine transferase in cell transformation by fos.

Authors:  A V Bakin; T Curran
Journal:  Science       Date:  1999-01-15       Impact factor: 47.728

7.  AP-1 Gene Expression Levels May Be Correlated with Changes in Gene Expression of Some Stemness Factors in Colon Carcinomas.

Authors:  Panagiotis Apostolou; Maria Toloudi; Eleni Ioannou; Marina Chatziioannou; Eleni Kourtidou; Ioanna Vlachou; Ioannis Papasotiriou
Journal:  J Signal Transduct       Date:  2013-12-11

8.  Identification of molecular signature of head and neck cancer stem-like cells.

Authors:  Shubham Shrivastava; Robert Steele; Melanie Sowadski; Susan E Crawford; Mark Varvares; Ratna B Ray
Journal:  Sci Rep       Date:  2015-01-15       Impact factor: 4.379

9.  Cancer stem cell markers in head and neck squamous cell carcinoma.

Authors:  Aidan G Major; Luke P Pitty; Camile S Farah
Journal:  Stem Cells Int       Date:  2013-03-03       Impact factor: 5.443

10.  Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling.

Authors:  Ananthi Rajamoorthi; Shubham Shrivastava; Robert Steele; Pratibha Nerurkar; Juan G Gonzalez; Susan Crawford; Mark Varvares; Ratna B Ray
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

View more
  42 in total

1.  Differential gene expression and network analysis in head and neck squamous cell carcinoma.

Authors:  Insan Habib; Farah Anjum; Taj Mohammad; Md Nayab Sulaimani; Alaa Shafie; Mazen Almehmadi; Dharmendra Kumar Yadav; Sukhwinder Singh Sohal; Md Imtaiyaz Hassan
Journal:  Mol Cell Biochem       Date:  2022-02-10       Impact factor: 3.396

2.  AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.

Authors:  Abdulmelik Aytatli; Neslisah Barlak; Fatma Sanli; Hasan Onur Caglar; Betul Gundogdu; Arzu Tatar; Michael Ittmann; Omer Faruk Karatas
Journal:  Cell Oncol (Dordr)       Date:  2021-11-27       Impact factor: 6.730

3.  The FnBPA from methicillin-resistant Staphylococcus aureus promoted development of oral squamous cell carcinoma.

Authors:  Li-Xin Kong; Zheng Wang; Yu-Ke Shou; Xue-Dong Zhou; Ya-Wen Zong; Ting Tong; Min Liao; Qi Han; Yan Li; Lei Cheng; Biao Ren
Journal:  J Oral Microbiol       Date:  2022-07-15       Impact factor: 5.833

Review 4.  Reporters of Cancer Stem Cells as a Tool for Drug Discovery.

Authors:  Amrutha Mohan; Reshma Raj R; Gayathri Mohan; Padmaja K P; Tessy Thomas Maliekal
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

5.  c-Fos mediates α1, 2-fucosyltransferase 1 and Lewis y expression in response to TGF-β1 in ovarian cancer.

Authors:  Yingying Hao; Liancheng Zhu; Limei Yan; Juanjuan Liu; Dawo Liu; Na Gao; Mingzi Tan; Song Gao; Bei Lin
Journal:  Oncol Rep       Date:  2017-10-23       Impact factor: 3.906

Review 6.  The Role of p16INK4a Pathway in Human Epidermal Stem Cell Self-Renewal, Aging and Cancer.

Authors:  Daniela D'Arcangelo; Lavinia Tinaburri; Elena Dellambra
Journal:  Int J Mol Sci       Date:  2017-07-22       Impact factor: 5.923

7.  Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization.

Authors:  Patrick O Bolan; Asaf Zviran; Lisa Brenan; Joshua S Schiffman; Neville Dusaj; Amy Goodale; Federica Piccioni; Cory M Johannessen; Dan A Landau
Journal:  Cell Syst       Date:  2019-10-23       Impact factor: 10.304

8.  ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness.

Authors:  Qingyu Luo; Xiaowei Wu; Wan Chang; Pengfei Zhao; Yabing Nan; Xiaolin Zhu; Jonathan P Katz; Dan Su; Zhihua Liu
Journal:  Cell Death Differ       Date:  2019-12-12       Impact factor: 15.828

9.  Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation.

Authors:  Peixin Dong; Ying Xiong; Sharon J B Hanley; Junming Yue; Hidemichi Watari
Journal:  J Exp Clin Cancer Res       Date:  2017-10-26

10.  AP-1 confers resistance to anti-cancer therapy by activating XIAP.

Authors:  Yuan Wang; Guo-Hui Wan; Ying-Min Wu; Hong-Sheng Wang; Hai-Fang Wang; Ge Zhang; Lin-Lin Lu; Zi-Qian Li; Ka-Ying Chan; Yan Zhou; Shao-Hui Cai; Yi-Fei Qi; Jun Du
Journal:  Oncotarget       Date:  2018-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.